Literature DB >> 18685832

The role of M1 muscarinic cholinergic receptors in the discriminative stimulus properties of N-desmethylclozapine and the atypical antipsychotic drug clozapine in rats.

Adam J Prus1, Alan L Pehrson, Scott D Philibin, Jesse T Wood, Sarah A Vunck, Joseph H Porter.   

Abstract

RATIONALE: The discriminative stimulus properties of clozapine (CLZ) have been studied for decades because it remains the prototype for atypical antipsychotic drug effects and yet is unique in many ways, including increased efficacy in treatment-resistant schizophrenia and in reducing suicidality. Recent studies have indicated that the active CLZ metabolite N-desmethylclozapine (NDMC) may play a role in mediating the cognitive efficacy of CLZ and may also have atypical antipsychotic properties.
OBJECTIVES: The present study sought to determine if NDMC has discriminative stimulus properties similar to that of its parent drug CLZ.
MATERIALS AND METHODS: Rats were trained to discriminate 1.25 mg/kg CLZ from vehicle in a two-choice drug discrimination task.
RESULTS: Although NDMC (2.5-20.0 mg/kg) failed to substitute for CLZ, the combination of NDMC (5.0 and 10.0 mg/kg) with a low dose (0.3125 mg/kg) of CLZ produced full substitution (>80% CLZ-appropriate responding) for the 1.25 mg/kg CLZ training dose. Co-administration of the M1-preferring receptor antagonist trihexyphenidyl (6.0 mg/kg) with a 5.0 mg/kg dose of NDMC produced partial substitution (>60% to <80% CLZ-appropriate responding) for CLZ, while administration of trihexyphenidyl alone (0.3-12.0 mg/kg) failed to substitute for CLZ.
CONCLUSIONS: These findings suggest that NDMC produces discriminative stimulus effects that are different from those elicited by its parent drug CLZ. This difference may be due to the agonist properties of NDMC at M(1) muscarinic cholinergic receptors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18685832     DOI: 10.1007/s00213-008-1262-0

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  29 in total

Review 1.  Discriminative stimulus properties of antipsychotics.

Authors:  A J Goudie; J A Smith
Journal:  Pharmacol Biochem Behav       Date:  1999-10       Impact factor: 3.533

2.  The discriminative stimulus effects of clozapine in pigeons: involvement of 5-hydroxytryptamine1C and 5-hydroxytryptamine2 receptors.

Authors:  E M Hoenicke; S A Vanecek; J H Woods
Journal:  J Pharmacol Exp Ther       Date:  1992-10       Impact factor: 4.030

3.  Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.

Authors:  A Schotte; P F Janssen; W Gommeren; W H Luyten; P Van Gompel; A S Lesage; K De Loore; J E Leysen
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

4.  The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine's actions?

Authors:  Marilyn A Davies; Beth Ann Compton-Toth; Sandra J Hufeisen; Herbert Y Meltzer; Bryan L Roth
Journal:  Psychopharmacology (Berl)       Date:  2004-10-13       Impact factor: 4.530

5.  Discriminative stimulus properties of the atypical neuroleptic clozapine in rats: tests with subtype selective receptor ligands.

Authors:  A J Goudie; J A Smith; A Taylor; M A Taylor; M D Tricklebank
Journal:  Behav Pharmacol       Date:  1998-12       Impact factor: 2.293

6.  Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine.

Authors:  E Scholz; J Dichgans
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1985

7.  Scopolamine impairs auditory delayed matching-to-sample performance in monkeys.

Authors:  Bethany Plakke; Chi-Wing Ng; Amy Poremba
Journal:  Neurosci Lett       Date:  2008-04-10       Impact factor: 3.046

8.  Caffeine attenuates scopolamine-induced memory impairment in humans.

Authors:  W Riedel; E Hogervorst; R Leboux; F Verhey; H van Praag; J Jolles
Journal:  Psychopharmacology (Berl)       Date:  1995-11       Impact factor: 4.530

9.  Discriminative stimulus properties of the atypical antipsychotic clozapine and the typical antipsychotic chlorpromazine in a three-choice drug discrimination procedure in rats.

Authors:  Joseph H Porter; Adam J Prus; Robert E Vann; Stephen A Varvel
Journal:  Psychopharmacology (Berl)       Date:  2004-08-13       Impact factor: 4.530

10.  Discriminative stimulus properties of 1.25 and 5.0 mg/kg doses of clozapine in rats: examination of the role of dopamine, serotonin, and muscarinic receptor mechanisms.

Authors:  Adam J Prus; Lisa E Baker; Herbert Y Meltzer
Journal:  Pharmacol Biochem Behav       Date:  2004-02       Impact factor: 3.533

View more
  5 in total

1.  Drug discrimination: 30 years of progress.

Authors:  Joseph H Porter; Adam J Prus
Journal:  Psychopharmacology (Berl)       Date:  2009-02-19       Impact factor: 4.530

2.  Relationship between plasma clozapine/N-desmethylclozapine and changes in basal forebrain-dorsolateral prefrontal cortex coupling in treatment-resistant schizophrenia.

Authors:  Deepak K Sarpal; Annie Blazer; James D Wilson; Finnegan J Calabro; William Foran; Charles E Kahn; Beatriz Luna; K N Roy Chengappa
Journal:  Schizophr Res       Date:  2022-04-02       Impact factor: 4.662

Review 3.  Discriminative stimulus properties of atypical and typical antipsychotic drugs: a review of preclinical studies.

Authors:  Joseph H Porter; Adam J Prus
Journal:  Psychopharmacology (Berl)       Date:  2008-09-16       Impact factor: 4.530

4.  Schizophrenia pathophysiology: are we any closer to a complete model?

Authors:  Shaheen E Lakhan; Karen F Vieira
Journal:  Ann Gen Psychiatry       Date:  2009-05-15       Impact factor: 3.455

5.  Weight gain, schizophrenia and antipsychotics: new findings from animal model and pharmacogenomic studies.

Authors:  Fabio Panariello; Vincenzo De Luca; Andrea de Bartolomeis
Journal:  Schizophr Res Treatment       Date:  2010-12-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.